Amy McMichael, MD, and Maria Lopes, MD, MS, review the major differences in quality of life, the impact on patients, and the costs and burdens associated with absenteeism or presentism.
Ryan Haumschild, PharmD, MS, MBA: You talked a lot about emotional well-being and emotional health as part of the considerations for patients [with psoriasis], but there are other differences in quality of life. What are some of those differences in quality of life that you see with your patients, and how are they impacting them on a day-to-day basis?
Amy McMichael, MD: If patients have very severe psoriasis—we talked about the thickening of the actual lesions, which tend to be a little more aggressive in patients of color—on their palms and feet, then that makes it impossible to walk and do anything with their hands. That’s 1 of the real indications that we need to go to a systemic medication and get you on it immediately, so that you can perform and give back to your community, do what you need to do at home. Location and thickness certainly make a difference in terms of quality of life.
Scalp involvement, which is so visible when it comes down onto the facial area, is much more common in patients of color, particularly with hypopigmentation and scaling. That has to be addressed more aggressively. Patients of color, especially women, often don’t wash their hair every day, so giving them an antidander shampoo and telling them to use it daily is going to be met with a significant amount of frustration. You have to understand the cultural background of that patient. How many times a week can you wash your hair? Let me give you something that you leave in the hair, leave on the scalp, so you can treat this disease. Even if we’re treating it systemically, sometimes we need to treat it topically to help with scale removal and anti-inflammatory treatment. Those are 2 of the bigger areas. We’ve touched on the other 1, which is the pigmentation or the dyschromia that psoriasis itself leaves. That can be very emotionally draining for patients, to deal with all this pigment even after the disease has improved.
Ryan Haumschild, PharmD, MS, MBA: You talked about psoriasis on the hands and feet. Many of us on a day-to-day basis utilize our extremities to do work, to stay active, to engage with our family members. But when I think about an employer, if we have patients with psoriasis, I want them to be high functioning, to pursue their passions and work, and to be productive employees of our organization. That’s what the employees a lot of times want. Unfortunately, when you’re living with psoriasis, that can’t always be the case. There might be some absenteeism that occurs with some patients.
I’ll turn to Dr Lopes as 1 of our managed care experts. When you think about some of these other costs associated with the disease, what are some of the costs and burdens that you think about associated with absenteeism and presenteeism that might relate to a patient with psoriasis?
Maria Lopes, MD, MS: That falls under the indirect costs. The data are critical. When there are absent data, we don’t know. In a peer-reviewed journal, the Journal of American Academy of Dermatology, this question was attempted in 2015. [A study] looked at health care resource utilization around different levels of severity for psoriasis, trying to quantify the impact on indirect costs. One of the findings from the study was that it correlates with a level of severity. Particularly for patients with moderate to severe psoriasis, the number of missed workdays increased. The percentage of patients no longer able to carry on full-time functions increased. Overall, a quarter of patients reported some level of work impairment.
It’s difficult to get your arms around how big the problem is. A lot of this can be self-reported, but it definitely has an impact. When you think about what this leads to, whether it’s depression, anxiety, or function, or other comorbidities, there’s an impact on workforce productivity, lost time from work, and psychosocial balance on these patients are functioning.
Ryan Haumschild, PharmD, MS, MBA: I appreciate you providing context to those indirect costs. That’s essential.
Transcript edited for clarity.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More